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ABSTRACT 
We examined the effects of fish oil (FO) on high-cholesterol diet-induced hepatic lipid 
accumulation and oxidative stress. Female C57BL/6J mice were fed diets consisting of 
safflower oil (SO), 1 en% FO (1FO), 2 en% FO (2FO), or 20 en% FO (20FO) with or without 
2 weight% (wt%) cholesterol (SO/CH, 1FO/CH, 2FO/CH, and 20FO/CH groups, 
respectively) for 8 weeks. The hepatic triacylglyceride levels were significantly lower in the 
2FO/CH and 20FO/CH groups than in the SO/CH group. The hepatic mRNAs of fatty acid 
oxidation-related genes were upregulated and the fatty acid synthesis-related genes were 
downregulated by the FO feeding. Adverse effects were not observed in the plasma levels of 
indicators of oxidative stress in response to the consumption of FO up to 20 en%. These 
results suggest that FO consumption in the range of 2–20 en% prevents hepatic lipid 
accumulation, thus improving lipid metabolism without causing oxidative stress. 
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1.  Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a simple form of hepatic steatosis, the 
additional presence of oxidative stress and stimulating inflammatory cytokines results in 
non-alcoholic steatohepatitis. NAFLD is recognized as one of the most common causes of 
chronic liver disease, and it is closely associated with cardiovascular diseases and diabetes 
[1-3]. Thus, preventing lipid accumulation in the liver may be a promising method for 
improving insulin resistance, diabetes, and other metabolic syndromes. 
It has been demonstrated that eicosapentaenoic acid (EPA) consumption improves hepatic 
steatosis [4]. A 12-month supplementation of n-3 polyunsaturated fatty acids (PUFAs; 1-g 
capsule daily) improved liver steatosis in NAFLD patients [5], and fish oil (FO) consumption 
reduces the risk of developing cardiovascular disease by decreasing the plasma triglyceride 
density [6]. Furthermore, many findings have indicated that the effects of n-3 PUFAs and FO 
are observed due to the inhibition of fatty acid synthesis via suppression of the expression of 
lipogenic genes such as sterol regulatory element-binding protein (SREBP), fatty acid 
synthase (FAS), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) 1 and 
the induction of fatty acid oxidation by activating peroxisome proliferator-activated receptor 
(PPAR) α, which is a nuclear receptor that regulates acyl-CoA oxidase (AOX) and 
uncoupling protein (UCP) 2 in the liver [7-15]. Many previous studies including ours used 
high dosages of FO [20–50 energy% (en%)] to investigate the physiological effects of FO 
[7-9, 12-16]. However, our latest research demonstrated that low doses of FO (2 or 5 en%) 
improved hepatic lipid accumulation induced by high-cholesterol diet consumption [17]. As 
described above, it has been demonstrated that PUFAs in FO improve lipid metabolism. 
However, EPA and docosahexaenoic acid (DHA), the major PUFAs of FO, are very 
susceptible to oxidation, which tends to generate free radicals and lipid peroxides that can 
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have adverse health effects. The oxidative stress caused by free radicals and lipid peroxides 
induces diabetes and other diseases [18]. In previous studies using FO, EPA and DHA were 
reported to increase the lipid peroxides levels in plasma and the liver [19, 20]. Conversely, 
other reports indicated that lipid peroxide levels were not increased by PUFA feeding [21, 22]. 
To study the effects of FO consumption, it is very important to assess both its efficacy and 
toxicity. 
In this study, to evaluate the minimum effective dose and toxicity of FO, we examined the 
influence of 1, 2, and 20 en% FO with or without 2 weight% (wt%) cholesterol on lipid 
metabolism and oxidative stress.  
 
2.  Material and methods 
2.1. Animals and diets 
 Female C57BL/6J mice were obtained from Tokyo Laboratory Animals Science Co. (Tokyo, 
Japan) at 7 weeks of age and fed a normal laboratory diet (MF, Oriental Yeast Co, Tokyo, 
Japan) for 1 week to acclimatize the animals to their new conditions. Animals were reared in 
a room with controlled temperature (23 ± 2°C), humidity (55 ± 10%), and a 12-h day cycle 
(7:00 AM-7:00 PM) at the Josai University Life Science Center. The mice were divided into 
six groups (n = 5 in each group). All groups were fed a diet containing 60 en% carbohydrates, 
20 en% fat, and 20 en% protein with or without 2 wt% cholesterol (CH). The details of the 
diets and abbreviated expressions (experimental groups) are shown in Table 1. β-Corn starch, 
casein, sucrose, cellulose powder, AIN-93G mineral mix, and AIN-93 vitamin mix were 
obtained from Oriental Yeast Co., Ltd (Tokyo, Japan). L-cysteine, t-butylhydroquinone, and 
cholesterol were obtained from Wako Pure Chemical Industries, Ltd (Osaka, Japan). In this 
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study, dietary fats consisted of a mixture of safflower oil (SO) and FO to maintain the total 
fat energy level at 20 en% (20 en% SO/0 en% FO, 19 en% SO/1 en% FO, 18 en% SO/2 en% 
FO, or 0 en% SO/20 en% FO). SO (Benibana Foods, Tokyo, Japan) contained 78 wt% oleic 
acid (18:1n-9). FO (NOF Co., Tokyo, Japan) contained 7 wt% EPA (20:5n-3), 24 wt% DHA 
(22:6n-3), and 1 wt% α-tocopherol. Feed and water were freely provided. The feed was 
changed at 10:00 AM every day, and the residual quantity was measured daily. All animal 
studies were conducted in accordance with the “Standards Relating to the Care and 
Management of Experimental Animals” (Notice No. 6 of the Office of Prime Minister dated 
March 27, 1980) and the guidelines of Institutional Animal Care and Use Committee of Josai 
University. 
 
2.2. Computed tomography (CT) 
After 8 weeks of feeding, the mice were starved for 3 h and intraperitoneally anesthetized 
with pentobarbital sodium (Dainippon Sumitomo Pharma, Osaka, Japan). The abdominal 
composition of the mice was examined by X-ray CT (LaTheta LCT-100, Aloka, Tokyo, 
Japan). Contiguous 2-mm slice images between the second lumbar (L2) and fourth lumbar 
(L4) were used for the quantitative assessment using LaTheta software (version 2.10). Fat 
was divided into visceral and subcutaneous fat and evaluated quantitatively. 
 
2.3. Collection of blood and tissue samples 
 After CT, the animals were dissected. Blood samples were drawn from the inferior vena 
cava and treated with EDTA-2Na. The liver and white adipose tissues (WATs) around the 
uterus were removed immediately and weighed. Photographs of the liver were taken using a 
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digital camera. A piece of liver tissue was excised from the median lobe of the liver. Five 
liver samples were individually collected for each group and fixed with 10% neutral buffered 
formalin (Wako Pure Chemical Industries, Ltd). The samples were embedded in paraffin, cut 
into sections, and stained with hematoxylin-eosin (H&E) for histopathological examination 
by Kotobiken Medical Laboratories, Inc. (Tokyo, Japan). Plasma was obtained by 
centrifugation (900×g, 4°C, 10 min) and frozen at −80°C for storage until analysis. The 
organs removed were frozen in liquid nitrogen and stored at −80°C. 
 
2.4. Quantification of hepatic and plasma lipids 
Hepatic lipids were extracted from approximately 100 mg of liver tissue for each mouse in 
accordance with the method of Folch et al [23]. Triacylglyceride and total cholesterol in the 
liver were measured using Triglyceride E-Test and Cholesterol E-Test kits (Wako Pure 
Chemical Industries, Ltd), respectively. Quantification of plasma triacylglyceride and total 
cholesterol levels was performed using the same test kits. To measure plasma high-density 
lipoprotein (HDL) cholesterol levels, HDL-Cholesterol E-Test kit (Wako Pure Chemical 
Industries, Ltd) was used. 
 
2.5. Quantification of mRNA expression 
 Total RNA was extracted from the liver and intestinal tissue of each mouse using Trizol 
(Invitrogen) in accordance with the manufacturer’s protocol. Quantification of mRNA 
expression levels by real-time RT-PCR was performed using the ABI Prism 7500 Sequence 
Detection System (Applied Biosystems, Foster City, CA, USA). mRNA was amplified using 
QuantiTect SYBP Green and QuantiTect RT Mix (Qiagen, Hilden, Germany). The thermal 
cycling conditions were as follows: reverse transcription at 50°C for 30 min, initial activation 
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at 95°C for 15 min, 40 cycles of denaturation at 94°C for 15 s, annealing at 55°C for 30 s, 
and extension at 72°C for 1 min. A housekeeping transcript, glyceraldehyde-3-phosphate 
dehydrogenase, was used as an endogenous control gene. The primers used for real-time PCR 
analysis are listed in supplementary Table S1. 
 
2.6. Assessment of oxidative stress 
The diacron of reactive oxygen metabolites (d-ROMs) test was used to assess lipid 
peroxidation and was performed according to a commercially available method (d-ROMs test, 
Free Radical Analytical System, Diacron, Grosseto, Italy). Plasma was obtained from the tail 
vein 0, 1, 4, and 8 weeks after experimental diet feeding. The observed data were expressed 
in conventional units (Carratelli Units, U.CARR), and 1 U.CARR corresponds to 0.8 mg/L 
hydrogen peroxide (H2O2). 
 
2.7. Statistical analysis 
Data were represented as the mean ± SD. A one-way analysis of variance (ANOVA) was 
performed on the data. Differences among groups were compared using Tukey-Kramer test. 
Statistical significance was defined as P < 0.05. 
 
3.  Results 
3.1. Food intake and body and tissue weight 
 Food intake (kcal/5 mice/day) during the study was comparable among the diet groups. 
Although final body weight increased in all groups, body weight gain, i.e., final body weight 
− initial body weight, was not significantly different among the groups. Liver weights were 
significantly increased by the intake of diet containing 2 wt% cholesterol with SO or 1 en% 
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FO. No large differences were observed in liver weight among the other groups. Compared 
with the SO group, WAT weight tended to be lower in the 20FO/CH group (Table 2). 
 
3.2. Assessment of abdominal fat tissues using X-ray CT 
Visceral fat levels were not changed by low-dose FO feeding. However, the 20FO group 
exhibited a tendency of decreased visceral fat compared with the SO group (Fig. 1B). 
Subcutaneous fat levels were also similar (Fig. 1C). 
 
3.3. Liver morphology, histology, and lipid levels 
 The morphology and histology of the liver are shown in Fig. 2. The livers of the SO/CH 
group mice were pale (Fig. 2A), and many lipid droplets were detected in tissue specimens 
(Fig. 2B). Compared with the SO/CH group, the 1FO/CH group displayed slightly less liver 
discoloration. In the 2FO/CH group, the discoloration was further suppressed and the amount 
of lipid droplets decreased. The livers of the 20FO and 20FO/CH group mice had a normal 
color and displayed no lipid droplets. 
As shown in Fig. 3A, hepatic triacylglyceride levels were significantly increased by the 
intake of diet containing 2 wt% cholesterol with SO or low-dose FO (1 and 2 en%). 
Compared with the SO/CH group, the 1FO/CH group exhibited no change in triacylglyceride 
levels; however, the triacylglyceride levels were tended to decreased in the 2FO/CH group. 
Hepatic total cholesterol levels in the SO/CH, 1FO/CH, and 2FO/CH groups were increased 
significantly by the supplementation of dietary cholesterol (Fig. 3B). However, the 1FO/CH 
and 2FO/CH groups exhibited significantly decreased total cholesterol levels compared with 
the SO/CH group. Hepatic total cholesterol and triacylglyceride levels were similar between 
the 20FO and 20FO/CH groups. 
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 3.4. Plasma lipid levels 
Plasma triglyceride levels were not significantly different among the groups (Fig. 4B). 
Plasma total cholesterol levels were increased by the supplementation of dietary cholesterol 
in all diet groups. Total cholesterol levels were similar among the SO, 1FO, and 2FO groups, 
but the 20FO group displayed significantly decreased total cholesterol levels compared with 
the SO group (Fig. 4C). HDL cholesterol levels were decreased significantly in the 20FO 
group compared with the SO group, and the decreased levels were markedly increased by 
cholesterol feeding (Fig. 4D). 
 
3.5. Liver mRNA expression levels of genes involved in lipid metabolism 
 To examine the effects of FO and cholesterol consumption on lipid metabolism in the liver, 
the mRNA expression of lipid metabolism-related genes was measured (Table 3). SREBP-1c, 
FAS, and SCD1 mRNA levels were not different between the SO and low-dose (1 and 2 en%) 
FO groups. FAS mRNA levels were reduced by cholesterol supplementation, but SCD-1 
mRNA levels were not affected. Conversely, in the 20 en% FO groups, FAS and SCD-1 
mRNA levels were significantly lower than those in the SO group, irrespective of cholesterol 
supplementation. The mRNA levels of AOX, a PPARα target gene involved in fatty acid 
oxidation, were significantly higher in the 20 en% FO groups than in the SO groups, 
irrespective of cholesterol supplementation. And, the mRNA levels of UCP-2, which is 
involved in heat production, were also significantly higher in the 20 en% FO groups. The 
expression of these genes did not increase significantly in low-dose (1 and 2 en%) FO groups. 
SREBP-2 mRNA levels were significantly lower in the cholesterol supplementation groups 
than in the no cholesterol supplementation groups. The mRNA levels of HMG-CoA reductase, 
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a rate-limiting enzyme of cholesterol synthesis, did not change in response to low-dose FO 
consumption alone, but they were reduced by cholesterol supplementation. In contrast, the 20 
en% high-dose FO groups displayed significantly lower HMG-CoA reductase mRNA levels 
than the SO group. The mRNA levels of ABCG5 and G8, two cholesterol transporters, were 
increased in all cholesterol-supplemented groups, except the 20FO/CH groups. The mRNA 
levels of cholesterol 7 α-hydroxylase, which is involved in bile acid synthesis, tended to 
increase with cholesterol supplementation. Catalase (CAT) mRNA levels were not 
significantly different among the groups. The mRNA levels of superoxide dismutase (SOD), 
which are antioxidant enzymes, were significantly increased in the 20FO group compared 
with the SO group. Cholesterol loading did not affect the expression of these genes. 
 
3.6. Oxidative stress 
 Oxidative stress indices are shown in Fig. 5. Regarding plasma d-ROM levels after 
experimental diet feeding for 1, 4, and 8 weeks, significant changes were not observed in 
response to FO and/or cholesterol feeding at any point. In all groups, d-ROM levels were 
high after 4 weeks of experimental diet feeding, but thereafter, further increases were not 
observed. Plasma thiobarbituric acid reactive substances (TBARS) levels tended to be lower 
in the 20 en% FO groups. However, major changes were not observed in response to FO and 
cholesterol feeding. 
 
4.  Discussion 
In this study, to determine the minimum effective dose of FO for improving lipid 
metabolism and to examine the effect of FO on oxidative stress, female C57BL/6J mice were 
fed diets containing 1, 2, or 20 en% FO with or without 2 wt% cholesterol for 8 weeks.  
10 
 
Body weight and parametrial WAT weight were not different among the 1FO, 2FO, and SO 
groups, but a decreasing tendency was observed in the 20FO group compared with the SO 
group. Previous studies described that high-dose FO feeding decreased body and WAT weight 
[16, 24, 25]; however, low-dose FO consumption did not affect these parameters [8, 17]. The 
present results are consistent with those of these reports. 
Excessive accumulation of lipids in the liver, which is one of the causes of NAFLD, is 
involved in the development of insulin resistance and cardiovascular disease. Consistent with 
our previous reports [16, 17], it is suggested that in addition to high-dose FO intake, low-dose 
2 en% FO intake, which is a common intake level in Japanese, can prevent fatty liver 
provoked by high-cholesterol diets. However, it is suggested that the suppressive effect is not 
sufficient at a dose of 1 en% FO. These results indicate that the 2 en% FO intake in daily 
meals is effective for preventing fatty liver. 
We examined the effects of low-dose FO and cholesterol feeding on the expression of lipid 
metabolism-related genes in the liver. HMG-CoA reductase and SREBP-2 mRNA levels 
tended to decrease in response to cholesterol loading. Conversely, the mRNA levels of 
ABCG5 and ABCG8, which are induced by LXR and involved in biliary sterol excretion, 
were increased by cholesterol supplementation. It is considered that cholesterol is reduced in 
the liver to maintain cholesterol homeostasis in the body. In the 1 and 2 en% FO groups, FAS 
and SCD-1 mRNA levels were not significantly different from those in the SO group. Hepatic 
PPARα and AOX mRNA levels were tended to increase in the 2 en% FO groups. And, in the 
20 en% FO group, in line with a previous report [16], the expression of fatty acid 
synthesis-related genes decreased and that of fatty acid oxidation-related gene increased 
significantly compared with the expression of these genes in the SO group. These results 
suggested that the inhibition of lipid accumulation in the liver by the 2 and 20 en% FO intake 
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was the result of changes in the expression of genes involved in lipid metabolism in the liver.  
EPA and DHA, the major PUFAs of FO, are very susceptible to peroxidation because of 
their high degree of unsaturation. Some previous studies reported that EPA or DHA 
consumption increased lipid peroxide levels in plasma and the liver [19, 20]. Tsuduki et al. 
[26] reported that FO intake increases oxidative stress, decreases cellular function, and causes 
organ dysfunction in senescence-accelerated (SAMP8) mice, thereby promoting aging and 
shortening the lifespan of mice. However, in this study, the plasma TBARS levels were not 
increased by FO intake up to 20 en%. Moreover, the plasma TBARS levels in the 20FO 
group tended to be lower compared with those in the SO group. The plasma levels of 
d-ROMs, a marker of oxidative stress, were not significantly different among the groups at 
any stage. Some reports described that FO intake aggravated oxidation stress [19, 20]. 
However, Frenoux et al. [22] reported that PUFA supplementation enhances the total 
anti-oxidant status and resistance to lipid peroxidation. In addition, Calviello et al. [21] 
reported that low doses of dietary EPA and DHA did not increase the susceptibility to 
oxidative stress. In this study, the mRNA expression of SOD and CAT, which are involved in 
enzymatic antioxidant, was observed. SOD was significantly increased and CAT tended to 
increase in the 20FO groups compared with the SO groups. These results suggest the 
possibility that oxidation stress was not increased because antioxidant enzyme activities were 
elevated. However, further examination is needed regarding this issue in the future.  
In conclusion, consumption of FO containing 2–20 en% fat prevents hepatic lipid 
accumulation, thus improving lipid metabolism without inducing oxidative stress. 
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Legends for figures and tables 
Fig. 1.  CT-based fat tissues composition analysis of 16-week-old female mice. 
 Representative X-ray CT images of mice fed SO, SO/CH, 1FO, 1FO/CH, 2FO, 2FO/CH, 
20FO, and 20FO/CH for 8 weeks, at the L3 level (A). The areas indicated with pink, yellow, 
and light-blue are visceral fat, subcutaneous fat, and muscle, respectively. CT-estimated 
amounts of visceral fat (B), and subcutaneous fat (C) in the abdominal area of L2–L4. Values 
represent means ± S.D. (n=4-5). Means with different letters are different at the p<0.05 level 
by Tukey-Kramer test. 
 
Fig. 2.  Liver morphology and tissue histology of 16-week-old female mice. 
 Liver morphology (A) , H&E-stained liver sections (B) in mice fed SO, SO/CH, 1FO, 
1FO/CH, 2FO, 2FO/CH, 20FO, and 20FO/CH for 8 weeks.  
 
Fig. 3.  Hepatic lipid levels of 16-week-old female mice. 
Hepatic triacylglyceride (TAG) (A) and total cholesterol (TC) (B) in mice fed SO, SO/CH, 
1FO, 1FO/CH, 2FO, 2FO/CH, 20FO, and 20FO/CH for 8 weeks. Values represent means ± 
S.D. (n=4-5). Means with different letters are different at the p<0.05 level by Tukey-Kramer 
test. 
 
Fig. 4. Blood glucose and plasma lipid levels of 16-week-old female mice.  
Blood glucose (A), triacylglyceride (TAG) (B), Total cholesterol (TC) (C), and high-density 
lipoprotein cholesterol (HDL-C) (D) in mice fed SO, SO/CH, 1FO, 1FO/CH, 2FO, 2FO/CH, 
20FO, and 20FO/CH for 8 weeks. Values represent means ± S.D. (n=4-5). Means with 
different letters are different at the p<0.05 level by Tukey-Kramer test. 
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 Fig. 5. Plasma d-ROMs and TBARS levels of 16-week-old female mice.   
Plasma d-ROMs for 0,1,4,8 weeks of experimental diets fed (A). Plasma d-ROMs for 8 
weeks of experimental diets fed (B) and plasma TBARS for 8 weeks of experimental diets 
fed (C). Values represent means ± S.D. (n=4-5). Statistical significance is indicated for 
the†-2FO compared to the SO. Means with different letters are different at the p<0.05 level 
by Tukey-Kramer test.  
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Table 1. Composition of the experimental diets 
*Vitamin mix and mineral mix were based on the AIN-93G formation. Vitamin mix substituted 0.25% sucrose for choline bitartrate. 
 Diet SO SO/CH 1FO  1FO/CH  2FO  2FO/CH  20FO  20FO/CH  
Ingredients(g)  
Safflower oil  8 8 7.2 7.2 6 6 - - 
Fish oil  - - 0.4 0.4 0.8 0.8 8 8 
Casein 20 20 20 20 20 20 20 20 
Sucrose 10.37 10.37 10.37 10.37 10.37 10.37 10.37 10.37 
β-starch  51.83 51.83 51.83 51.83 51.83 51.83 51.83 51.83 
Vitamin mix *  1 1 1 1 1 1 1 1 
Mineral mix  3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
Cellulose powder 5 5 5 5 5 5 5 5 
L-cysteine 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
Tert-butyl 
hydroquinone 0.0016 0.0016 0.0016 0.0016 0.0016 0.0016 0.0016 0.0016 
cholesterol - 2 - 2 - 2 2 2 
Total(g)  100 102 100 102 100 102 102 102 
Energy (kcal/100g) 374.02 366.68 374.02 366.68 374.02 366.68 366.68 366.68 
Fat Energy ratio (%)  19.7 19.7 19.7 19.7 19.7 19.7 19.7 19.7 
Table 2. Body and tissue weight of 16-week-old female mice   
Values represent means ± S.D. (n=4-5). Means with different letters are different at the p<0.05 level by Tukey–Kramer test. 
Parameter SO SO/CH 1FO 1FO/CH 2FO 2FO/CH 20FO 20FO/CH 
Initial body weight (g) 16.70  ± 1.11  16.68  ± 0.93  16.66  ± 0.82  16.66  ± 0.78  16.68  ± 0.70  16.66  ± 0.70  16.68  ± 0.65  16.76  ± 0.66  
final body weight (g) 21.05  ± 1.65  22.14  ± 2.22  22.06  ± 2.05  22.52  ± 1.19  22.60  ± 2.06  22.35  ± 1.30  20.51  ± 1.12  22.20  ± 0.52  
Liver weight (g) 0.92  ± 0.12bc 1.28  ± 0.13a 
 
0.91  ± 0.09c 1.09  ± 0.09b 0.90  ± 0.13c 0.96  ± 0.10bc 0.85  ± 0.06c 1.00  ± 0.06bc 
Liver weight/body weight (%) 4.38  ± 0.42bc 5.64  ± 0.32a 4.96  ± 1.91bc 4.83  ± 0.19ab 3.98  ± 0.28bc 4.29  ± 0.19bc 4.13  ± 0.31c 4.51  ± 0.20bc 
White adipose tissue weight (g) 0.32  ± 0.17  0.46  ± 0.22  0.52  ± 0.29  0.51  ± 0.11  0.49  ± 0.09  0.45  ± 0.13  0.20  ± 0.10  0.41  ± 0.16  
Table 3. Expression of genes associated with lipid metabolism in the liver 
The mRNA expression levels in liver of mice fed SO, SO/CH, 1FO, 1FO/CH, 2FO, and 2FO/CH for 8 weeks. Values represent means ± S.D. 
(n=4-5). Means with different letters are different at the p<0.05 level by Tukey–Kramer test. 
SO SO/CH 1FO 1FO/CH 2FO 2FO/CH 20FO 20FO/CH 
SREBPs 
SREBP-1c 1.00  ± 0.26ab 1.29  ± 0.38a 0.97  ± 0.29ab 1.68  ± 0.45a 0.93  ± 0.04ab 1.28  ± 0.66a 0.41  ± 0.45b 0.40  ± 0.13b 
SREBP-2 1.00  ± 0.12a 0.48  ± 0.05b 0.96  ± 0.18a 0.48  ± 0.05b 0.80  ± 0.2a 0.44  ± 0.03b 0.79  ± 0.15a 0.40  ± 0.05b 
Fatty acid biosynthesis 
FAS 1.00  ± 0.47a 0.46  ± 0.07ac 0.61  ± 0.3ac 0.41  ± 0.17ac 0.90  ± 0.58ab 0.35  ± 0.06bc 0.14  ± 0.02c 0.17  ± 0.11c 
SCD1 1.00  ± 0.40a 1.21  ± 0.34a 0.97  ± 0.35a 1.20  ± 0.18a 0.97  ± 0.41a 1.14  ± 0.16a 0.11  ± 0.06b 0.35  ± 0.17b 
Cholesterol homeostasis 
HMG-CoA Reductase 1.00  ± 0.43a 0.37  ± 0.08ab 1.00  ± 0.44a 0.45  ± 0.11ab 0.93  ± 0.47a 0.45  ± 0.07ab 0.40  ± 0.11ab 0.30  ± 0.08b 
ABCG5 1.00  ± 0.30c 1.74  ± 0.60ab 1.07  ± 0.24c 2.09  ± 0.50a 1.10  ± 0.15bc 1.94  ± 0.65ac 1.10  ± 0.23bc 1.16  ± 0.29bc 
ABCG8 1.00  ± 0.27bc 1.43  ± 0.28ac 1.07  ± 0.40c 1.67  ± 0.24a 1.01  ± 0.22bc 1.66  ± 0.34ab 0.98  ± 0.22bc 1.00  ± 0.28bc 
Fatty acid β-oxidation  
PPARα 1.00  ± 0.19b 1.10  ± 0.33ab 1.17  ± 0.19ab 1.46  ± 0.31ab 1.44  ± 0.41ab 1.64  ± 0.06a 1.58  ± 0.45b 1.64  ± 0.13ab 
AOX 1.00  ± 0.21d 1.20  ± 0.19cd 1.07  ± 0.19cd 1.40  ± 0.25bd 1.34  ± 0.19cd 1.49  ± 0.09bc 1.86  ± 0.37ab 2.07  ± 0.26a 
UCP2 1.00  ± 0.16cd 0.86  ± 0.14cd 1.20  ± 0.34bc 0.70  ± 0.08d 1.21  ± 0.22bc 0.80  ± 0.17cd 1.71  ± 0.11a 1.57  ± 0.29ab 
Bile acid bioynthesis 
CYP7A1 1.00  ± 0.95  1.71  ± 0.82  1.28  ± 1.03  1.29  ± 1.03  0.80  ± 0.42  2.30  ± 1.20  0.35  ± 0.20  1.07  ± 0.18  
CYP8B1 1.00  ± 0.38b 1.78  ± 0.45b 1.63  ± 0.51b 1.10  ± 0.26b 1.22  ± 0.53b 1.57  ± 0.12b 3.20  ± 0.48a 3.33  ± 0.37a 
Antioxidant enzyme 
CAT 1.00  ± 0.10  0.97  ± 0.13  0.96  ± 0.14  1.12  ± 0.16  1.07  ± 0.06  1.08  ± 0.09  1.20  ± 0.12  1.15  ± 0.19  
SOD 1.00  ± 0.01c 1.03  ± 0.13c 1.07  ± 0.11bc 1.18  ± 0.13ac 1.10  ± 0.11ac 1.22  ± 0.17ac 1.29  ± 0.07ab 1.32  ± 0.07a 
